Aggressive Lung Squamous Cell Carcinoma With Tumor Extension Into the Heart
This lung cancer diagnosis at a glance
- Subtype
- Squamous Cell Carcinoma
- Biomarkers
- PD-L1 high (TPS 95%)
- Sex
- male
- Treatment
- radiation, chemotherapy and immunotherapy
- Outcome
- In Memory
Treatment course, step by step
- Received an airway stent and outpatient palliative radiation after the tumor compressed the main bronchi.
- About 1 month after diagnosis, started paclitaxel, carboplatin and pembrolizumab.
What happened, in summary
A 51-year-old man presented with coughing up blood, weight loss, reduced appetite, chest discomfort, and worsening shortness of breath. Imaging showed a very large mass extending from the mediastinum into the left upper lung, left main bronchus, and left atrium. Biopsy confirmed a poorly differentiated non-small cell lung carcinoma favoring squamous cell histology.
The tumor formed a large intracardiac thrombus that occupied much of the left atrium and moved toward the left ventricle. Surgery was considered unsafe because of extensive involvement of critical cardiac structures. Within 2 weeks, the intracardiac tumor had grown substantially and airway compression worsened. A Y-shaped airway stent improved breathing, and he received outpatient palliative radiation.
Tumor testing showed very high PD-L1 expression at 95%. About 1 month after diagnosis, he began paclitaxel, carboplatin, and pembrolizumab. Despite treatment, his condition deteriorated rapidly. He died 3 months after the initial diagnosis and 2 months after starting systemic therapy.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- PD-L1 Positive Lung Cancer 21 stories
- Carboplatin for Lung Cancer 168 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer